PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 26327771
OWN - NLM
STAT- MEDLINE
DCOM- 20161005
LR  - 20161230
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Linking)
VI  - 21
IP  - 32
DP  - 2015 Aug 28
TI  - Efficacy of hepatic resection vs transarterial chemoembolization for solitary
      huge hepatocellular carcinoma.
PG  - 9630-7
LID - 10.3748/wjg.v21.i32.9630 [doi]
AB  - AIM: To compare the efficacy of hepatic resection (HR) and transarterial
      chemoembolization (TACE) for patients with solitary huge (>/= 10 cm)
      hepatocellular carcinoma (HCC). METHODS: Records were retrospectively analyzed of
      247 patients with solitary huge HCC, comprising 180 treated by HR and 67 by TACE.
      Long-term overall survival (OS) was compared between the two groups using the
      Kaplan-Meier method, and independent predictors of survival were identified by
      multivariate analysis. These analyses were performed using all patients in both
      groups and/or 61 pairs of propensity score-matched patients from the two groups. 
      RESULTS: OS at 5 years was significantly higher in the HR group than the TACE
      group, across all patients (P = 0.002) and across propensity score-matched pairs 
      (36.4% vs 18.2%, P = 0.039). The two groups showed similar postoperative
      mortality and morbidity. Multivariate analysis identified alpha-fetoprotein >/=
      400 ng/mL, presence of vascular invasion and TACE treatment as independent
      predictors of poor OS. CONCLUSION: Our findings suggest that HR can be safe and
      more effective than TACE for patients with solitary huge HCC.
FAU - Zhu, Shao-Liang
AU  - Zhu SL
AD  - Shao-Liang Zhu, Jian-Hong Zhong, Yang Ke, Liang Ma, Xue-Mei You, Le-Qun Li,
      Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical
      University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Zhong, Jian-Hong
AU  - Zhong JH
AD  - Shao-Liang Zhu, Jian-Hong Zhong, Yang Ke, Liang Ma, Xue-Mei You, Le-Qun Li,
      Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical
      University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Ke, Yang
AU  - Ke Y
AD  - Shao-Liang Zhu, Jian-Hong Zhong, Yang Ke, Liang Ma, Xue-Mei You, Le-Qun Li,
      Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical
      University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Ma, Liang
AU  - Ma L
AD  - Shao-Liang Zhu, Jian-Hong Zhong, Yang Ke, Liang Ma, Xue-Mei You, Le-Qun Li,
      Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical
      University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - You, Xue-Mei
AU  - You XM
AD  - Shao-Liang Zhu, Jian-Hong Zhong, Yang Ke, Liang Ma, Xue-Mei You, Le-Qun Li,
      Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical
      University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Li, Le-Qun
AU  - Li LQ
AD  - Shao-Liang Zhu, Jian-Hong Zhong, Yang Ke, Liang Ma, Xue-Mei You, Le-Qun Li,
      Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical
      University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (AFP protein, human)
RN  - 0 (alpha-Fetoproteins)
SB  - IM
MH  - Adult
MH  - Carcinoma, Hepatocellular/blood/mortality/secondary/*therapy
MH  - *Chemoembolization, Therapeutic/adverse effects/mortality
MH  - Female
MH  - *Hepatectomy/adverse effects/mortality
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Liver Neoplasms/blood/mortality/pathology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neoplasm Invasiveness
MH  - Neoplasm Recurrence, Local
MH  - Propensity Score
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
MH  - *Tumor Burden
MH  - alpha-Fetoproteins/analysis
PMC - PMC4548124
OID - NLM: PMC4548124
OTO - NOTNLM
OT  - Hepatic resection
OT  - Overall survival
OT  - Propensity score matching
OT  - Solitary huge hepatocellular carcinoma
OT  - Transarterial chemoembolization
EDAT- 2015/09/04 06:00
MHDA- 2016/10/07 06:00
CRDT- 2015/09/02 06:00
PHST- 2015/02/11 00:00 [received]
PHST- 2015/03/29 00:00 [revised]
PHST- 2015/07/08 00:00 [accepted]
PHST- 2015/09/02 06:00 [entrez]
PHST- 2015/09/04 06:00 [pubmed]
PHST- 2016/10/07 06:00 [medline]
AID - 10.3748/wjg.v21.i32.9630 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2015 Aug 28;21(32):9630-7. doi: 10.3748/wjg.v21.i32.9630.